The Latest Breaking News from Amgen

Despite Amgen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.45%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.48%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.